Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Nanophase Technologies (NANX) -- Ignore unavailable to you. Want to Upgrade?

To: Crossy who wrote (122)	3/16/1998 10:46:00 PM
From: Obewon	Read Replies (1) \| Respond to of 322

OF COURSE it's going to affect the current quarters revenue. Considering that NANX's revenues last quarter was a mere $100,000 if the Itochou agreement's payment was removed, I'd say the company would be hard pressed to have revenues this quarter above $200,000 let alone $1M. I agree that Chemfirst is in a much stronger position that Moyco seeing that it at least is currently doing business with the semiconductor manufacturers that it must convince to drop Cabot's slurries. However, until Chemfirst lands a full scale production contract for its NANX containing slurry, NANX won't see any revenues until late in the second quarter at earliest. Personally, I'm amazed at the company's product and technology and am convinced that long-term it will be extremely successful. However, the short-term uncertainty (which should resolve itself by the end of NEXT quarter) combined with a shortage of funds on my part keep me from investing at this time. BUT - to answer your question: 1) affect of the AFC ; NONE (It has no significant revenues to be affected yet) 2) affect of pushing the ramp of NANX's contract out 2 quarters: NONE (The stock will move on just the first hint that it is shipping its product in bulk. For a company of NANX's size and characteristics, the exact quarter in which revenues start pouring in isn't as important as the sure knowledge that revenues will ramp up sometime in the future. In many ways it reminds me of a Biotech company.) 3) affect of non-recurring nature of Itochou's marketing payment: Revenues will be WAY DOWN! OB